BioMarin Files to Extend Voxzogo, Its CNP Peptide Growth Drug, to Hypochondroplasia and Brings Phase 3 Data to ASBMR 2026
BioMarin said on October 9, 2026 that it has submitted a supplemental application to the FDA for Voxzogo (vosoritide), a C-type natriuretic peptide analog approved for achondroplasia, in hypochondroplasia, a milder genetic form of short stature, with filings in Europe and other regions on track and a possible 2027 launch if approved. Phase 3 results showing faster growth in children with hypochondroplasia are among 13 studies the company is presenting at the ASBMR meeting in Boston, though the release gives no growth figures. A separate application with long-term achondroplasia data has an FDA decision date of February 28, 2027.